You are here

Hong Kong seeks to cash in on frenzy for Chinese biotech stocks

HK bourse is in the midst of weighing a proposal that would allow biotech firms to list before they turn a profit

BT_20180130_PQBIOTECH30_3285994.jpg
China's drug innovation has gained momentum in recent years, in part due to dramatic regulatory reforms to speed up approvals.

Hong Kong

CHINESE drug companies have been on a tear in the US stock market. Now, entrepreneurs and investors betting on the Asian country's fledgling biotechnology industry see another reason for optimism.

The stock exchange in Hong Kong - home to the world's fourth-largest equity

sentifi.com

Market voices on:

Powered by GET.comGetCom